YARW (YARW) FinancialsYARWYARW

Evaluating the bottom line, Yarrow Bioscience, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3197.94%, while the net margin is -2988.66%. These profitability ratios, combined with a Return on Equity (ROE) of -61.93%, provide a clear picture of how effectively YARW converts its operational activities into shareholder value.

In the context of the broader market, YARW competes directly with industry leaders such as VRCA and PTHS. With a market capitalization of $77.02M, it holds a significant position in the sector. When comparing efficiency, YARW's gross margin of 100.00% stands against VRCA's 85.02% and PTHS's 70.18%. Such benchmarking helps identify whether Yarrow Bioscience, Inc. is trading at a premium or discount relative to its financial performance.

Yarrow Bioscience has shown significant revenue potential with a projected total revenue of $202,000 for Q1 2025 and a consistent gross margin of 100% across its recent quarters, indicating strong product profitability.